| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
|
| [2] |
Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial[J]. J Clin Oncol, 2018, 36(11): 1080-1087. DOI: 10.1200/jco.2017.75.3657.
|
| [3] |
Shore ND, Morgans AK, Ryan CJ. Resetting the bar of castration resistance–understanding androgen dynamics in therapy resistance and treatment choice in prostate cancer[J]. Clin Genitourin Cancer, 2021, 19(3): 199-207. DOI: 10.1016/j.clgc.2020.08.008.
|
| [4] |
Jacob A, Raj R, Allison DB, et al. Androgen receptor signaling in prostate cancer and therapeutic strategies[J]. Cancers, 2021, 13(21): 5417. DOI: 10.3390/cancers13215417.
|
| [5] |
Ng K, Smith S, Shamash J. Metastatic hormone-sensitive prostate cancer (mHSPC): advances and treatment strategies in the first-line setting[J]. Oncol Ther, 2020, 8(2): 209-230. DOI: 10.1007/s40487-020-00119-z.
|
| [6] |
Hussain M, Fizazi K, Shore ND, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review[J]. JAMA Oncol, 2024, 10(6): 807-820. DOI: 10.1001/jamaoncol.2024.0591.
|
| [7] |
|
| [8] |
Choi E, Buie J, Camacho J, et al. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers[J]. Res Rep Urol, 2022, 14:87-108. DOI: 10.2147/RRU.S303215.
|
| [9] |
Bögemann M, Facchini G, Bauernhofer T, et al. Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice[J]. Ir J Med Sci, 2023, 192(6): 2643-2651. DOI: 10.1007/s11845-023-03303-y.
|
| [10] |
Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study[J]. J Clin Oncol, 2021, 39(20): 2294-2303. DOI: 10.1200/jco.20.03488.
|
| [11] |
Sweeney CJ, Martin AJ, Stockler MR, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2023, 24(4): 323-334. DOI: 10.1016/s1470-2045(23)00063-3.
|
| [12] |
Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer [J]. N Engl J Med, 2019, 381(2): 121-131. DOI: 10.1056/NEJMoa1903835.
|
| [13] |
Armstrong AJ, Azad AA, Iguchi T, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer[J]. J Clin Oncol, 2022, 40(15): 1616-1622. DOI: 10.1200/JCO.22.00193.
|
| [14] |
Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer[J]. J Clin Oncol, 2019, 37(32): 2974-2986. DOI: 10.1200/JCO.19.00799.
|
| [15] |
Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO guideline (2023)[J]. J Urol, 2023, 209(6): 1082-1090. DOI: 10.1097/JU.0000000000003452.
|
| [16] |
Fizazi K, Gillessen S, ESMO Guidelines Committee Electronic address: clinicalguidelines@esmo org. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents[J]. Ann Oncol, 2023, 34(6): 557-563. DOI: 10.1016/j.annonc.2023.02.015.
|
| [17] |
Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines ® Insights: prostate cancer, version 3.2024[J]. J Natl Compr Canc Netw, 2024, 22(3): 140-150. DOI: 10.6004/jnccn.2024.0019.
|
| [18] |
Tilki D, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 update: treatment of relapsing and metastatic prostate cancer[J]. Eur Urol, 2024, 86(2): 164-182. DOI: 10.1016/j.eururo.2024.04.010.
|
| [19] |
Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer[J]. Drug Des Devel Ther, 2012, 6: 13-18. DOI: 10.2147/DDDT.S15850.
|
| [20] |
Gasperoni L, Giunta EF, Montanari D, et al. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact[J]. Expert Opin Drug Metab Toxicol, 2024, 20(6): 491-502. DOI: 10.1080/17425255.2024.2353749.
|
| [21] |
Auchus RJ, Yu MK, Nguyen S, et al. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer[J]. Oncologist, 2014, 19(12): 1231-1240. DOI: 10.1634/theoncologist.2014-0167.
|
| [22] |
Baciarello G, Özgüroğlu M, Mundle S, et al. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: a post-hoc exploratory analysis of the LATITUDE study[J]. Eur J Cancer, 2022, 162: 56-64. DOI: 10.1016/j.ejca.2021.11.026.
|
| [23] |
James ND, Clarke NW, Cook A, et al. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476) [J]. Int J Cancer, 2022, 151(3): 422-434. DOI: 10.1002/ijc.34018.
|
| [24] |
Rydzewska LHM, Burdett S, Vale CL, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis[J]. Eur J Cancer, 2017, 84: 88-101. DOI: 10.1016/j.ejca.2017.07.003.
|
| [25] |
Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer[J]. Front Oncol, 2019, 9: 801. DOI: 10.3389/fonc.2019.00801.
|
| [26] |
Dalla Volta A, Valcamonico F, Zivi A, et al. Whole-body diffusion-weighted magnetic resonance imaging for assessment of the bone response rate in patients with metastatic hormone-sensitive prostate cancer receiving enzalutamide[J]. Eur Urol, 2024, 86(3): 268-271. DOI: 10.1016/j.eururo.2024.05.004.
|
| [27] |
Gu W, Han W, Luo H, et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(10): 1249-1260. DOI: 10.1016/S1470-2045(22)00507-1.
|
| [28] |
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南2025[M]. 北京: 人民卫生出版社, 2025.
|
| [29] |
James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial[J]. Lancet, 2016, 387(10024): 1163-1177. DOI: 10.1016/S0140-6736(15)01037-5.
|
| [30] |
Tucci M, Bertaglia V, Vignani F, et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis[J]. Eur Urol, 2016, 69(4): 563-573. DOI: 10.1016/j.eururo.2015.09.013.
|
| [31] |
Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial[J]. Eur Urol, 2016, 70(2): 256-262. DOI: 10.1016/j.eururo.2015.11.005.
|
| [32] |
Vale CL, Fisher DJ, Godolphin PJ, et al. Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials[J]. Lancet Oncol, 2023, 24(7): 783-797. DOI: 10.1016/S1470-2045(23)00230-9.
|
| [33] |
Smith MR, Hussain M, Saad F, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer [J]. N Engl J Med, 2022, 386(12): 1132-1142. DOI: 10.1056/NEJMoa2119115.
|
| [34] |
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design[J]. Lancet, 2022, 399(10336): 1695-1707. DOI: 10.1016/S0140-6736(22)00367-1.
|
| [35] |
Hussain M, Tombal B, Saad F, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial[J]. J Clin Oncol, 2023, 41(20): 3595-3607. DOI: 10.1200/jco.23.00041.
|
| [36] |
Gillessen S, Bossi A, Davis ID, et al. Management of patients with advanced prostate cancer. part I: intermediate-/ high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the advanced prostate cancer consensus conference 2022[J]. Eur Urol, 2023, 83(3): 267-293. DOI: 10.1016/j.eururo.2022.11.002.
|
| [37] |
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol, 2014, 65(6): 1058-1066. DOI: 10.1016/j.eururo.2013.11.012.
|
| [38] |
Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer[J]. J Clin Oncol, 2016, 34(24): 2835-2842. DOI: 10.1200/JCO.2016.67.4788.
|
| [39] |
Cho Y, Chang JS, Rha KH, et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?[J]. PLoS One, 2016, 11(1): e0147191. DOI: 10.1371/journal.pone.0147191.
|
| [40] |
Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial[J]. Eur Urol, 2019, 75(3): 410-418. DOI: 10.1016/j.eururo.2018.09.008.
|
| [41] |
Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease[J]. J Urol, 2002, 168(3): 1008-1012. DOI: 10.1016/S0022-5347(05)64562-4.
|
| [42] |
Sooriakumaran P, Karnes J, Stief C, et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J]. Eur Urol, 2016, 69(5): 788-794. DOI: 10.1016/j.eururo.2015.05.023.
|
| [43] |
Chaloupka M, Stoermer L, Apfelbeck M, et al. Health-related quality of life following cytoreductive radical prostatectomy in patients with de-novo oligometastatic prostate cancer[J]. Cancers, 2021, 13(22): 5636. DOI: 10.3390/cancers13225636.
|
| [44] |
Aydemir H, Kumsar Ş. Re: cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study: A. heidenreich, D. pfister and D. porres J urol 2015;193: 832-838[J]. J Urol, 2015, 194(3): 853-854. DOI: 10.1016/j.juro.2015.02.2952.
|
| [45] |
Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry[J]. Eur Urol, 2014, 66(3): 602-603. DOI: 10.1016/j.eururo.2014.04.009.
|
| [46] |
Aydemir H, Kumsar Ş. Re: cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study: A. heidenreich, D. pfister and D. porres J urol 2015;193: 832-838[J]. J Urol, 2015, 194(3): 853-854. DOI: 10.1016/j.juro.2015.02.2952.
|
| [47] |
Tsuboi I, Matsukawa A, Kardoust Parizi M, et al. A systematic review and meta-analysis of the impact of local therapies on local event suppression in metastatic hormone-sensitive prostate cancer[J]. Eur Urol Oncol, 2024, 7(6): 1185-1194. DOI: 10.1016/j.euo.2024.03.007.
|
| [48] |
Patrikidou A, Brureau L, Casenave J, et al. Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, management, and disease outcome[J]. Urol Oncol Semin Orig Investig, 2015, 33(5): 202.e9-202.e17. DOI: 10.1016/j.urolonc.2015.01.022.
|
| [49] |
Bianchini D, Lorente D, Rescigno P, et al. Effect on overall survival of locoregional treatment in a cohort of de novo metastatic prostate cancer patients: a single institution retrospective analysis from the royal marsden hospital[J]. Clin Genitourin Cancer, 2017, 15(5): e801-e807. DOI: 10.1016/j.clgc.2017.04.013.
|
| [50] |
Paolieri F, Sammarco E, Ferrari M, et al. Front-line therapeutic strategy in metastatic hormone sensitive prostate cancer: an updated therapeutic algorithm[J]. Clin Genitourin Cancer, 2024, 22(4): 102096. DOI: 10.1016/j.clgc.2024.102096.
|
| [51] |
Mutlu H, Bozcuk H. The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis[J]. J Cancer Res Ther, 2023, 19(2): 394-402. DOI: 10.4103/jcrt.JCRT_23_20.
|
| [52] |
Hoeh B, Garcia CC, Wenzel M, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume[J]. Eur Urol Focus, 2023, 9(5): 838-842. DOI: 10.1016/j.euf.2023.03.024.
|
| [53] |
Schaeffer EM, Srinivas S, Adra N, et al. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2023, 21(10): 1067-1096. DOI: 10.6004/jnccn.2023.0050.
|
| [54] |
Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL[J]. Ann Oncol, 2016, 27(2): 286-294. DOI: 10.1093/annonc/mdv542.
|
| [55] |
De Giorgi U, Hussain M, Shore N, et al. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region[J]. Eur J Cancer, 2021, 159: 237-246. DOI: 10.1016/j.ejca.2021.10.015.
|
| [56] |
Shen J, Chowdhury S, Agarwal N, et al. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN[J]. Br J Cancer, 2024, 130(1): 73-81. DOI: 10.1038/s41416-023-02492-8.
|
| [57] |
Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial[J]. Lancet, 2018, 392(10162): 2353-2366. DOI: 10.1016/S0140-6736(18)32486-3.
|
| [58] |
Gravis G, Boher JM, Chen YH, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies[J]. Eur Urol, 2018, 73(6): 847-855. DOI: 10.1016/j.eururo.2018.02.001.
|
| [59] |
Ghannam Y, Laville A, Kirova Y, et al. Radiotherapy of the primary disease for synchronous metastatic cancer: a systematic review[J]. Cancers, 2022, 14(23): 5929. DOI: 10.3390/cancers14235929.
|
| [60] |
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial[J]. JAMA Oncol, 2020, 6(5): 650. DOI: 10.1001/jamaoncol.2020.0147.
|
| [61] |
Verzoni E, Pappagallo G, Alongi F, et al. Achieving consensus for management of hormone-sensitive, low-volume metastatic prostate cancer in Italy[J]. Curr Oncol, 2022, 29(7): 4578-4586. DOI: 10.3390/curroncol29070362.
|
| [62] |
Deek MP, Sutera P, Jing Y, et al. Multi-institutional analysis of metastasis-directed therapy with or without androgen deprivation therapy in oligometastatic castration-sensitive prostate cancer[J]. Eur Urol Oncol, 2024, 7(6): 1403-1410. DOI: 10.1016/j.euo.2024.03.010.
|
| [63] |
Hussain M, Desai C, de Bono J. Olaparib in metastatic castration-resistant prostate cancer. reply[J]. N Engl J Med, 2021, 384(12): 1175-1176. DOI: 10.1056/NEJMc2100225.
|
| [64] |
Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial[J]. Lancet Oncol, 2020, 21(1): 162-174. DOI: 10.1016/S1470-2045(19)30684-9.
|
| [65] |
Ong S, O'Brien J, Medhurst E, et al. Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review[J]. Transl Androl Urol, 2021, 10(10): 3918-3930. DOI: 10.21037/tau-20-1118.
|
| [66] |
Sweeney C, Bracarda S, Sternberg CN, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet, 2021, 398(10295): 131-142. DOI: 10.1016/S0140-6736(21)00580-8.
|
| [67] |
Fizazi K, Clarke NW, de Santis M, et al. Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study[J]. Ann Oncol, 2026, 37(1): 53-68. DOI: 10.1016/j.annonc.2025.10.004.
|
| [68] |
Smith M, Piulats J, Todenhöfer T, et al. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2025, 26(11): 1489-1500. DOI: 10.1016/S1470-2045(25)00475-9.
|
| [69] |
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer [J]. N Engl J Med, 2021, 385(12): 1091-1103. DOI: 10.1056/NEJMoa2107322.
|
| [70] |
Prive BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study [J]. Clin Cancer Res, 2021, 27(13): 3595-3601. DOI: 10.1158/1078-0432.CCR-20-3317.
|
| [71] |
Satapathy S, Yadav MP, Ballal S, et al. Promising therapeutic activity of 177 Lu-PSMA-617 in synchronous high-volume metastatic hormone-sensitive prostate cancer: a pilot experience[J]. Clin Nucl Med, 2024, 49(2): 131-137. DOI: 10.1097/RLU.0000000000005000.
|
| [72] |
Al-Khanaty A, Chen D, Walbaum J, et al. Guideline of guidelines: lutetium-177PSMAradioligand therapy in advanced prostate cancer[J]. BJU Int, 2026: bju.70283. DOI: 10.1111/bju.70283.
|